Anaphylactoid reaction to hydroxycobalamin with tolerance of cyanocobalamin Sir, A patient with an anaphylactoid reaction to hydroxycobalamin but good tolerance of cyanocobalamin is described, which emphasizes the usefulness of challenge tests in cases of allergic or pseudoallergic reactions.
A 33-year-old woman with a history of Crohn's disease developed subacute combined degeneration of the spinal cord due to vitamin B 12 deficiency. Replacement therapy with hydroxycobalamin was established at a dose of 10 mg intramuscularly every month with no problems for more than a year. Unexpectedly, 2 hours after a dose, the patient developed generalised urticaria and angioedema with involvement of the upper airway. Prick and intradermal tests performed with 5 mg/ml and 100 jg/ml of hydroxycobalamin, respectively, were negative. Under in-hospital observation the patient was given 2500 gg of hydroxycobalamin by the intramuscular route; 20 min later, she experienced pruritus on her palms, shortly followed by generalised urticaria, prominent lip and palpebral oedema, hoarseness and chest tightness. The patient was treated with epinephrine, methylprednisolone and chlorpheniramine with total recovery in 2 hours. A challenge test with benzyl alcohol, added as preservative, was carried out with no reaction. On the basis that the neurologic manifestations would progress without adequate replacement treatment, a desensitisation protocol was developed. Increasing doses of hydroxycobalamin, beginning with 0.05 jg, were administered every 15 min by the intramuscular route. Ten minutes after the injection of 125 jg of hydroxycobalamin, the same allergic reaction appeared. Premedication with antihistamines did not provide reliably effective protection from the hydroxycobalamin-induced reaction in the patient. However, intramuscular challenge tests with cyanocobalamin up to 10 mg, performed on three different occasions, were followed by no reaction. At present, the patient receives 10 mg of cyanocobalamin monthly without problems.
Cobalamin is an organometallic vitamin which cannot be synthesized in the human body and must be supplied in the diet. The minimum daily requirement is about 2.5 jg. In patients with disease of the distal small intestine such as Crohn's disease, cobalamin deficiency may develop. In order to avoid clinical features of cobalamin deficiency, especially neurologic manifestations, replacement therapy is suggested. Because oral absorption is inadequate, replacement must be administered parenterally. The vitamin preparations which are used therapeutically are cyanocobalamin and hydroxycobalamin (both also called vitamin B12) given intramuscularly at monthly periods and maintained indefinitely. Allergic reactions to vitamin B 12 are rare but can be observed even after several years of treatment.' James and Warin reported one patient with dyspnoea and urticaria in the course of a treatment with cyanocobalamin and hydroxycobalamin in which specific IgE could not be showed, suggesting an anaphylactoid reaction rather than a real allergic mechanism.2 Recognising that a reaction is caused by direct histamine release may be important since treatment can generally be continued by lowering the dose of the drug. In the patient reported here, the immediate response obtained with low doses of hydroxycobalamin (125 jg This is an area which commands further study. Our policy of performing salvage angioplasty in the context of <50% ST segment resolution in the worst lead 2 hours after the initiation of thrombolytic therapy has produced favourable results, especially if the patient presents promptly, receives thrombolysis promptly and the 2-hour EGG is scrupulously reviewed. Our experience is that this policy can reduce mortality from an expected 17-20% to 5%. Thus, patients with persistent ST elevation following thrombolytic therapy should be considered early for
